火针四花穴对肺癌化疗患者IL-2、TNF-a、T细胞亚群的影响
|
摘要
目的：
通过采用前瞻性随机临床对照研究的方法,观察火针四花穴对肺癌化疗患者的临床疗效。了解火针四花穴对肺癌化疗患者细胞因子IL-2、TNF-a、T淋巴细胞亚群、化疗毒副反应、生存质量及体力状况的影响,从而确立一种减轻化疗毒副反应、减轻化疗引起的生存质量及体力状况下降的有效方法及有效穴对,探讨火针四花穴减轻肺癌化疗毒副反应、减轻化疗引起的生存质量及体力状况下降的可能作用机制。
方法：
将符合标准的60例肺癌化疗病人,采用简单随机法分为两组,以单纯化疗为对照组,以化疗配合火针四花穴治疗为治疗组。化疗：化疗方案采用紫杉醇联合顺铂或吉西他滨联合顺铂的联合化疗方案,常规应用预防化疗毒副反应的西药,进行为期一周的一疗程治疗。火针四花穴：双侧膈俞、胆俞穴局部消毒后,涂上一层薄薄的跌打万花油,用烧红的火针迅速准确地刺入穴位0.1mm,并敏捷出针,连续刺3下,用棉球按压针孔片刻,并再涂上一层薄薄的跌打万花油,1次／天,共7天。以细胞因子IL-2、TNF-a、T淋巴细胞亚群、抗癌药物毒性反应分度、生存质量表、Karnofasky体力状况评分作为疗效评价指标。所有指标均于化疗前1天及疗程结束后第2天评定一次,观察期为1周。应用所得数据建立数据库,采用SPSS19.0统计软件进行统计分析。
结果：
治疗前两组抗癌药物毒性反应分度,经统计学检验,差异无统计学差异(P>0.05)。治疗后两组抗癌药物毒性反应分度均较治疗前增高(P<0.05,P<0.01),但治疗组相对较轻(P<0.05),差异均有统计学意义；治疗组血液系统损害、胃肠道不适较对照组轻(P<0.01,P<0.05),差异有统计学意义。
治疗前两组生存质量评分、Karnofasky体力状况评分,经统计学检验,差异均无统计学差异(P>0.05)。治疗后,两组生存质量评分均较治疗前升高(P均<0.01),Karnofasky体力状况评分均较治疗前下降(P均<0.01),但治疗组生存质量评分较对照组低(P<0.05),Karnofasky体力状况评分较对照组高(P<0.05),差异有统计学意义。
治疗前两组IL-2、TNF-a、T淋巴细胞亚群水平,经统计学检验,差异均无统计学差异(P>0.05)。治疗后,治疗组IL-2水平较治疗前升高(P<0.01),TNF-a水平下降(P<0.01),CD3+、CD4+、CD8+、CD[／CD。+水平无明显变化(P>0.05)；对照组IL-2水平较治疗前升高(P<0.01),TNF-a水平无明显变化(P>0.05),CD3+、CD4+、CD4+/CD8+水平下降(P<0.01),CD8+水平升高(P<0.01)。两组治疗后比较,治疗组IL-2、CD3+、CD4+、CD4+／CD8+水平较对照组高(P均<0.01),TNF-a、CD8+水平较对照组低(P均<0.01),差异有显著统计学意义。
结论：
肺癌化疗患者配合火针四花穴可减轻化疗引起的生存质量、Karnofasky体力状况的下降；减轻抗癌药物毒性反应；减少化疗引起的血液系统损害、胃肠道不适；可在一定程度上提高IL-2水平,降低TNF-a水平,减轻化疗对T淋巴细胞亚群的损害。火针四花穴能减轻化疗毒副反应、减轻化疗引起的生存质量下降,可能与其能在一定程度上提高肺癌化疗患者的免疫功能有关。
Objecti ve
A prospective randomized controlled study on the clinic effects of Fire needle on SiHua in chemotherapy patients with lung cancer. To understand the effects on IL-2, TNF-a,T lymphocyte subsets level and the toxic and side reaction, quality of life,physical condition of Fire needle on SiHua in chemotherapy patients with lung cancer, trying to find effective treatments and a group of effective acupoints with fewer adverse effects of chemotherapy and the fall of the quality of life and physical condition in chemotherapy patients with lung cancer;to explore the possible mechanisms of reducing adverse effects and the fall of the quality of life and physical condition in chemotherapy patients with lung cancer.
Methods
60eligible lung cancer patients with chemotherapy were simple randomly divided into two groups, the control group with simple chemotherapy and the treatment group with chemotherapy plus fire needle on SiHua. The chemotherapy included the combination chemotherapy with paclitaxel and Cisplat in or Gemcitabine plus Cisplatin, with the conventional medicine for preventing adverse effeets of chemotherapy. A week made a course.As for the fire needle on SiHua, after the local disinfection of the bilateral Geshu and Dashu points, a thin layer of Dedawanhua oil was apllied on SiHua. Then the red-hot fire needle quickly and accurately picked acupoints0.1mm by3times, and was pulled out agility. Then, using a cotton ball to press the acupoints for a moment, and a thin layer of Dedawanhua oil was apllied on the points. The course contains one treatment a day for7days. Before and after the treatment, the IL-2level, TNF-a level, T lymphocyte subsets level, anti-cancer drug toxicity assessment classification level, quality of life and Karnofasky score were separately evaluated as efficacy indicator with one week observation period. All the data were collected into a database and were analyzed by SPSS19.0statistical software.
Results
Before the treatment, there were no significant differences in the ant i-cancer drug toxicity assessment classification level between the two gr oups (P>0.05). After the treatment, the anti-cancer drug toxicity assessment classification level increased(p<0.05, p<0.01) in two groups,but it was re latively mild in treatment group(p<0.05).The damage to the blood system a nd the gastrointestinal discomforts of chemotherapy in treatment group re duced(P<0.01, P<0.05).
Before the treatment, there were no significant differences in the qua lity of life and Karnofasky score between the two groups(P>0.05). After th e treatment, the quality of life score of two groups were increased(p<0.01),the Karnofasky score were decreased(p<0.01), the quality of life score of treatment group reduced(p<0.05) compared with the control group and th e Karnofasky score of treatment group increased (p<0.05) compared with the control group.
Before the treatment, there were no significant differences in the IL-2level, TNF-a level. IL-2level, lymphocyte subsets level between the two g roups (P>0.05). After the treatment, the IL-2level of treatment group incre ased (p<0.01),the TNF-a level of treatment group reduced(P<0.01), and there were no significant change(p>0.05) in the CD3-、CD4-、CD8-、CD4+、/CD8-Level of t reatment group;the IL-2level of control group increased(p<0.01), the CD3+、 CD4+、CD4+/CD8+Level of control group reduced (p<0.01) and the CD8-Level of c ontrol group increased(P<0.01), there was no significant change(p>0.05)in the TNF-a level of control group. After the treatment, the IL-2level and CD3+、CD4+、CD4+/CD8+Level of treatment group increased (P<0.01) compared with the control group and the TNF-a level and CD8+Level of treatment groupred uced(P<0.01) compared with the control group.
Conclusion
Combined chemotherapy of fire needle on SiHua can reduce anti-cancer drug toxicity assessment classification level;and it can reduce the damage of blood system and gastrointestinal discomfort caused by chemotherapy;and it can reduce the fall of the quality of life and physical condition by the chemotherapy;and it can increase the IL-2level, decrease the TNF-a level of the chemotherapy patients with lung cancer in a certain extent, and reduce the damage on T lymphocyte subsets by the chemotherapy. Fire needle on SiHua can reduce the adverse effects and the fall of the quality of life in patients with chemotherapy, may be related to a certain extent improve immune function in chemotherapy patients with lung cancer.
通过采用前瞻性随机临床对照研究的方法,观察火针四花穴对肺癌化疗患者的临床疗效。了解火针四花穴对肺癌化疗患者细胞因子IL-2、TNF-a、T淋巴细胞亚群、化疗毒副反应、生存质量及体力状况的影响,从而确立一种减轻化疗毒副反应、减轻化疗引起的生存质量及体力状况下降的有效方法及有效穴对,探讨火针四花穴减轻肺癌化疗毒副反应、减轻化疗引起的生存质量及体力状况下降的可能作用机制。
方法：
将符合标准的60例肺癌化疗病人,采用简单随机法分为两组,以单纯化疗为对照组,以化疗配合火针四花穴治疗为治疗组。化疗：化疗方案采用紫杉醇联合顺铂或吉西他滨联合顺铂的联合化疗方案,常规应用预防化疗毒副反应的西药,进行为期一周的一疗程治疗。火针四花穴：双侧膈俞、胆俞穴局部消毒后,涂上一层薄薄的跌打万花油,用烧红的火针迅速准确地刺入穴位0.1mm,并敏捷出针,连续刺3下,用棉球按压针孔片刻,并再涂上一层薄薄的跌打万花油,1次／天,共7天。以细胞因子IL-2、TNF-a、T淋巴细胞亚群、抗癌药物毒性反应分度、生存质量表、Karnofasky体力状况评分作为疗效评价指标。所有指标均于化疗前1天及疗程结束后第2天评定一次,观察期为1周。应用所得数据建立数据库,采用SPSS19.0统计软件进行统计分析。
结果：
治疗前两组抗癌药物毒性反应分度,经统计学检验,差异无统计学差异(P>0.05)。治疗后两组抗癌药物毒性反应分度均较治疗前增高(P<0.05,P<0.01),但治疗组相对较轻(P<0.05),差异均有统计学意义；治疗组血液系统损害、胃肠道不适较对照组轻(P<0.01,P<0.05),差异有统计学意义。
治疗前两组生存质量评分、Karnofasky体力状况评分,经统计学检验,差异均无统计学差异(P>0.05)。治疗后,两组生存质量评分均较治疗前升高(P均<0.01),Karnofasky体力状况评分均较治疗前下降(P均<0.01),但治疗组生存质量评分较对照组低(P<0.05),Karnofasky体力状况评分较对照组高(P<0.05),差异有统计学意义。
治疗前两组IL-2、TNF-a、T淋巴细胞亚群水平,经统计学检验,差异均无统计学差异(P>0.05)。治疗后,治疗组IL-2水平较治疗前升高(P<0.01),TNF-a水平下降(P<0.01),CD3+、CD4+、CD8+、CD[／CD。+水平无明显变化(P>0.05)；对照组IL-2水平较治疗前升高(P<0.01),TNF-a水平无明显变化(P>0.05),CD3+、CD4+、CD4+/CD8+水平下降(P<0.01),CD8+水平升高(P<0.01)。两组治疗后比较,治疗组IL-2、CD3+、CD4+、CD4+／CD8+水平较对照组高(P均<0.01),TNF-a、CD8+水平较对照组低(P均<0.01),差异有显著统计学意义。
结论：
肺癌化疗患者配合火针四花穴可减轻化疗引起的生存质量、Karnofasky体力状况的下降；减轻抗癌药物毒性反应；减少化疗引起的血液系统损害、胃肠道不适；可在一定程度上提高IL-2水平,降低TNF-a水平,减轻化疗对T淋巴细胞亚群的损害。火针四花穴能减轻化疗毒副反应、减轻化疗引起的生存质量下降,可能与其能在一定程度上提高肺癌化疗患者的免疫功能有关。
Objecti ve
A prospective randomized controlled study on the clinic effects of Fire needle on SiHua in chemotherapy patients with lung cancer. To understand the effects on IL-2, TNF-a,T lymphocyte subsets level and the toxic and side reaction, quality of life,physical condition of Fire needle on SiHua in chemotherapy patients with lung cancer, trying to find effective treatments and a group of effective acupoints with fewer adverse effects of chemotherapy and the fall of the quality of life and physical condition in chemotherapy patients with lung cancer;to explore the possible mechanisms of reducing adverse effects and the fall of the quality of life and physical condition in chemotherapy patients with lung cancer.
Methods
60eligible lung cancer patients with chemotherapy were simple randomly divided into two groups, the control group with simple chemotherapy and the treatment group with chemotherapy plus fire needle on SiHua. The chemotherapy included the combination chemotherapy with paclitaxel and Cisplat in or Gemcitabine plus Cisplatin, with the conventional medicine for preventing adverse effeets of chemotherapy. A week made a course.As for the fire needle on SiHua, after the local disinfection of the bilateral Geshu and Dashu points, a thin layer of Dedawanhua oil was apllied on SiHua. Then the red-hot fire needle quickly and accurately picked acupoints0.1mm by3times, and was pulled out agility. Then, using a cotton ball to press the acupoints for a moment, and a thin layer of Dedawanhua oil was apllied on the points. The course contains one treatment a day for7days. Before and after the treatment, the IL-2level, TNF-a level, T lymphocyte subsets level, anti-cancer drug toxicity assessment classification level, quality of life and Karnofasky score were separately evaluated as efficacy indicator with one week observation period. All the data were collected into a database and were analyzed by SPSS19.0statistical software.
Results
Before the treatment, there were no significant differences in the ant i-cancer drug toxicity assessment classification level between the two gr oups (P>0.05). After the treatment, the anti-cancer drug toxicity assessment classification level increased(p<0.05, p<0.01) in two groups,but it was re latively mild in treatment group(p<0.05).The damage to the blood system a nd the gastrointestinal discomforts of chemotherapy in treatment group re duced(P<0.01, P<0.05).
Before the treatment, there were no significant differences in the qua lity of life and Karnofasky score between the two groups(P>0.05). After th e treatment, the quality of life score of two groups were increased(p<0.01),the Karnofasky score were decreased(p<0.01), the quality of life score of treatment group reduced(p<0.05) compared with the control group and th e Karnofasky score of treatment group increased (p<0.05) compared with the control group.
Before the treatment, there were no significant differences in the IL-2level, TNF-a level. IL-2level, lymphocyte subsets level between the two g roups (P>0.05). After the treatment, the IL-2level of treatment group incre ased (p<0.01),the TNF-a level of treatment group reduced(P<0.01), and there were no significant change(p>0.05) in the CD3-、CD4-、CD8-、CD4+、/CD8-Level of t reatment group;the IL-2level of control group increased(p<0.01), the CD3+、 CD4+、CD4+/CD8+Level of control group reduced (p<0.01) and the CD8-Level of c ontrol group increased(P<0.01), there was no significant change(p>0.05)in the TNF-a level of control group. After the treatment, the IL-2level and CD3+、CD4+、CD4+/CD8+Level of treatment group increased (P<0.01) compared with the control group and the TNF-a level and CD8+Level of treatment groupred uced(P<0.01) compared with the control group.
Conclusion
Combined chemotherapy of fire needle on SiHua can reduce anti-cancer drug toxicity assessment classification level;and it can reduce the damage of blood system and gastrointestinal discomfort caused by chemotherapy;and it can reduce the fall of the quality of life and physical condition by the chemotherapy;and it can increase the IL-2level, decrease the TNF-a level of the chemotherapy patients with lung cancer in a certain extent, and reduce the damage on T lymphocyte subsets by the chemotherapy. Fire needle on SiHua can reduce the adverse effects and the fall of the quality of life in patients with chemotherapy, may be related to a certain extent improve immune function in chemotherapy patients with lung cancer.
引文
[1]王瑾,许峰,周清华.第十一届世界肺癌大会专题肺癌流行病学研究进展[J].中国肺癌杂志,2005.10,8(5)：395-400.
[2]游伟程.常见恶性肿瘤的流行情况[J].中华医学信息导报,2005,20(22)：22.
[3]PirozynskiM.100 years of lung cancer[J]. Respir M ed,2006,100(12):2073-2084.
[4]KenjiW, Manami I, Tetsuya M, et al. Tobacco Smoking and Lung Cancer Risk:An Evalu ation Based on a Systematic Review of Epidemio-logical Evidence Among the Japanese P opulation[J]. Japanese Journal of Clinical Oncology,2006,36(5):309-324.
[5]Edwards R, PlessMT, HowelD, et al.Does living near heavy industry cause lung cane er in women? A case-control study using life grid inter-views[J]. Thorax,2006,61(1 2):1076-1082.
[6]Ignatius TS, Yuk LC, Joseph SK, et al.Dose-Response Relationship between Cooking Fumes Exposures and Lung Cancer among Chinese Non-smoking Women [J].Cancer Research, 2006,66(8):4961-4967.
[7]Darby S, HillD, DeoH, et al,Residential radon and lung cancer detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14 208 persons without lung cancer from 13 epidemiologic studies in Europe[J]. Scand J W ork Environ Health,2006,32(Suppll):1-83.
[8]Bellil Y, Edelman M J. Bronchogenic carcinoma in solid organ transplant recipients [J].Curr Treat Options Oncol,2006,7(1):77-81.
[9]Jun-ichiN, Manami I, Motoki I, et al. Association Between Lung Cancer Incidence and Family History of Lung Cancer [J]. Chest,2006,130:968-975.
[10]战忠利,孙雷娜.WHO 2004年版肺癌组织学分类与临床意义[J].中国肿瘤影像学,2009,2(2)：145-147.
[11]Pignon JP, Tribodet H, Scrag liotti G,et al.Lung Adjuvant Cisplstin Evaluation(LAC E):A pooled analysis of five randomized clinical trials including 4,584patients [J]. J C lin Oncol,2006,24:366.
[12]Stewart LA, Burdett S, Tiemey JF, et al. Surgery and adjuvant chemo-therapy(CT)compa red to surgery alone in nonsmall cell lung cancer(NSCLS):A meta-analysis using indiv idual patient data(IPD)from random ized clinical trials (RCT)[J]. JC lin Oncol,2007,25: 397.
[13]Scag liottiG, FossatiR, TorriV, et al. Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ, orⅢ Anon-small-cell lung cancer[J].JN atlCancer In st,2003,95:1453-1461.
[14]Arriagada R,Bergm an B,DunantA, et al. Cisplatin-based adjuvant chemotherapy in pa tients with completely resected non-small-cell lung cancers[J].N EnglJMed,2004,350:3 51-360.
[15]Winton T, Livingston R,Johnson D, et al. Vinorelbine plus cisplatin observation in reseceted non-small-cell lung cancers[J].N Engl JMed,2005,352:2589-2597.
[16]Strauss G,Hemdon J,Maddaus M, et al. Adjuvant chemotherapy in stage IB non-small-c ell lung cancers(NSCLC):Update of Cancer and Leukemia GroupB(CALGB)protoco19633[J].J Clin Oncol,2006,24:365.
[17]Douillard JY,Rosell R, DeLena M, et al. Adjuvant vinorelbine plus cisplatin versus observationg in patients with completely resected stage ⅠB—ⅢA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association ANIIA):A randomized con trolled trial [J]. Lancet Oncol,2006,7:719-727.
[18]孙威.非小细胞肺癌治疗进展[J].中华现代外科学杂志,2005,2(1)：60-62.
[19]PORT Meta-analysis Trialists Group, Postperative radiotherapy for non-small-cell lung Cancer[J]. G. The Cochrane Database of System Reviews,2005, Issue 2.
[20]Okawara G,Postoperative radiotherapy in stage Ⅱ or ⅢA completely resected non-small cell lung cancer a systematic review and practice guideline[J]. Lung Cancer,20 04,44:1-11.
[21]Choy H,Akerley Wsfran H. Multi institutional phase Ⅱ traill of paclitaxel, carbop latin and concurrent radiation therapy for locally advancednon-small-celllungcancer [J].JClinOncol,1998,16(10):3316-3322.
[22]Sandler AB, GrayR, Brahmer J, et al Paclitaxel-caboplatin alone or with bevacizumab for non-small cell lungcancer[J]. NEnglJMed,2006,355:2542-2550.
[23]夏述燕,赵体玉.术中125I放射性粒子种植治疗局部晚期非小细胞肺癌的手术配合[J].现代护理,2008,14(4)：524-525.
[24]艾星浩,陆舜,廖美琳.肺癌以手术为主的多学科综合治疗进展[J].中国肺癌杂志,2003,6(6)：441-443.
[25]孙燕.常见肿瘤综合治疗的进展.第八届全国临床肿瘤大会
[26]Dan L, Zhu B, Chen Z. Meta—analysis of the literature:Neoadjuvant chemotherapy versus surgery alone in non-small cell lung cancer[J]. J Clin Oncol,2008,26:a7580.
[27]Ciuleanu TE, Brodow icz T, Belani CP, et al. Maintenance pemetrexed plus best suppor tive care (BSC)versus placebo plus BSC;A phase Ⅲstudy [J].JClin Oncol,2008,26(Supp 1):8001.
[28]E1-Shenshawy HM. FathyA, Eteba S, et al. Sequential chemora-diotherapy versus concur rent chemoradio therapy plus consolilation chemotherapy in unresecetable stage III n on-small cell lung cancer [J].JClin Oncol,2008,26:18509.
[29]马玉英.肺癌的生物治疗研究与进展[J].中国医学研究与临床,2008,6(6)：35-41.
[30]Krause I,Valesini G, Scrivo R, Sheonfeld Y. Autoimmune aspects of cytokine and anti cytokine therapies[J]. Am Med,2003,115(5):390-7.
[31]朱小花,田应选.肺癌生物分子靶向治疗研究进展[J].实用医技杂志,2006,13(16)：492.
[32]Sandler AB,Gray R, Brahmer J, et al Paclitaxel-carboplatin alone or with bevacizum ab for non-small cell lungcaner[J]. N Engl JMed,2006,355:2542-2550.
[33]Ono M, Kuwano, LMolecular mechanisms of epidermal growth factor eceptor activatio n and response to gefitinib and other EGFR-targeting drugs [J].Clin Cancer Ras,2006, 12(24):7242.
[34]彭勇,张靓.非小细胞肺癌治疗进展研究[J].中国现代药物应用,2008,2(2)：95.
[35]任淑华,王井伟,刘长宏,等.肺癌患者血清中IL-2和TNF水平变化的临床意义[J].中国煤炭工业医学杂志,2002,15(5)：315.
[36]邹建文,程征,王大华.肺癌患者血清中IL-2,TNF-a测定的临床意义[J].放射免疫学杂志,2002,15(5)：315.
[37]孙昕.肺癌患者血清TNF-a和IL-6水平观察及临床意义[J].安徽医科大学学报,2001,36(1)：45-46.
[38]叶建增,申维玺,马慧利,等.TGF-β 1、TNF-α与癌症相关性乏力关系的免疫组化研究[J].医学研究杂志,2008,5(37)：38-40.
[39]XU, FU XY. Plate IFN-gammia induces cell growth inhibition by Fas-mediated apoptos is:uequirement of STATL. protein for up regulation of Fasand Faslexpression[J]. Cancer Res,1998,58(2):2832-2833.
[40]Ordirura M, Romano C, De Vita F, et al, Behaviour of interleukin-2 serum levels in a dvanced non-small cell lung cancer patients:relationship with responset otherapy and survival[J]. CancerImmunolImmunother,2009,49(10):530-536.
[41]Fischer JR,Schindel M, Bulzebruck H, et al. Long-term survival in small cell lung c ancer patients is correlated with high inteleukin-2 secretion at diagnosis[J]. JCance rResClinOncol,2000,126(12):730-73.
[42]张晓菊,张劲农,张建初.检测肺癌所致胸腔积液中Sil-2R的临床应用价值研究[J].新医学,2007,38(4)：232-233.
[43]陈晓琳,戴勇,李富荣,等.恶性肿瘤患者T细胞及NK细胞功能研究及临床意义[.T].中国现代医学杂志,2002,12(2)：41-43.
[44]李进东,许金良,王文光,等.肺癌患者外周血T细胞亚群的变化[J],中国医师进修杂志,2006,29(11)：25-27.
[45]姜维洁,董静懿.肺癌患者血管内皮生长因子和T细胞亚群表达的变化[J].标记免疫分析与临床,2006,13(4)：201-202.
[46]Nishikawa H. Kato T, Tawara Isao, et al, IFN-r controls the generation/activation of CD4+ CD25+ regulatory Tcells in antitum or immune response[J]. J Immunol,2005,175(7):44 33-4440.
[47]张敬川,王红兵,高超,等.非小细胞肺癌患者T细胞亚群变化的临床意义[J].徐州医学院学报,2002,22(6)：537-538.
[48]狄松波,陈清勇.非小细胞肺癌患者化疗前后细胞免疫功能的变化[J].实用医学杂志,2009,25(14)：2341-2342.
[49]黄谦,朱慕云,卞京文.肺癌患者IL-6及T淋巴细胞亚群检测的实验研究[J].江苏临床医学杂志,2001,5(6)：498-500.
[50]李和根.刘嘉湘教授以扶正法为主治疗肺癌经验[J].四川中医,2005,23(7)：5-6.
[51]刘嘉湘,施志明,徐振华,等.滋阴生津益气温阳法治疗晚期原发性肺癌的临床研究[J].中医杂志,1995,36(3)：155-158.
[52]吴玉生.肺癌病因病机与临床治疗[J].新中医,2005,37(8)：3-4.
[53]李际强,罗翌,徐凯.刘伟胜教授治疗肺癌经验介绍[J].新中医,2007,39(3)：99-100.
[54]张霆.从伏气学说探讨肺癌之病因病机[J].中医研究,2007,20(3)：5-7.
[55]郑红刚,花宝金.朴炳奎辨证治疗肺癌的学术思想[J].北京中医,2007,26(5)：273-275.
[56]高雪艳,林动,陈家俊.四君子汤为主在肺癌化疗过程中减轻胃肠道反应的观察[J].海峡药学,2009,21(12)：182-183.
[57]张东焱,郑燕飚,汪力慧,等.半苏散敷脐治疗肺癌化疗呕吐反应临床观察[J].中国误诊学杂志,2009.6,9(16)：3819-3820.
[58]杨祖贻,罗洁.中药对Ⅲ-Ⅳ期肺癌患者化疗骨髓抑制及生活质量的影响[J].四川中医,2003,23(2)：10-12.
[59]刘展华,史建文.复方阿胶浆对肺癌化疗增效减毒作用的临床观察[J].中华中医药学刊,2007,11.15(11)：2427-2428.
[60]吴小明.补肾健脾中药降低中晚期肺癌化疗毒副反应效果观察[J].中医药临床杂志,2010,10.22(5)：394-395.
[61]张印,郭建刚.复方阿胶浆对肺癌化疗增效减毒作用的临床观察[J].第四军医大学报,2005,26(13)：1219-1220.
[62]李兴琴,徐增年,周俊琴.“保肺泰”对C57BL/6J荷瘤小鼠及化疗荷瘤小鼠NK细胞活性的影响[J].实验动物科学与管理,2000,3.17(1)：27-29.
[63]杨焱,张越,景年才,等.电针足三里穴治疗恶性肿瘤化疗所致恶心呕吐：多中心随机对照研究[J].中国针灸,2009,12.29(12)：955-978.
[64]陈闯,张作军,黎汉忠,等.电针足三里穴对化疗减毒作用的临床观察[J].新中医,2004,3(3 6)： 46-47.
[65]李爱华.针刺治疗肝癌介入化疗栓塞术后顽固性呃逆疗效观察[J],湖北中医杂志,2005,27(7)： 38.
[66]唐玲.艾灸治疗化疗后胃肠道反应[J],中医外治杂志,2001,10(5)：48.
[67]李柳宁,孔怡琳,刘丽荣,等.雷火灸对含铂类药物化疗所致消化道反应25例[J].陕西中医,2009,30(7)：886-887.
[68]沈国伟,肖扬.针灸足三里对抗化疗呕吐反应临床研究[J].中国针灸,2001,21(3)：158-160.
[69]沈国伟.针灸对化疗呕吐患者胃电频谱分布和波形的影响[J].中国针灸,2001,(9)：7-8.
[70]沈国伟,赵京生.针灸对化疗呕吐患者的胃动力学影响[J].上海针灸杂志,2003,22(3)：18-21.
[71]彭秩霞,张亚密,潘改燕.足三里穴位注射防治化疗后消化道反应30例[J].陕西中医学院学报,2009.05,32(3)：33.
[72]闫文针.胃复安维生素B6针穴位注射治疗化疗后胃肠道反应疗效观察[J],中国误诊学杂志,2010.7,10(20)：4836.
[73]刑晓娟.电针加耳穴贴压治疗化疗引起的呕吐54例疗效比较[J],第四军医大学学报,2009,30(3)：354.
[74]王淑兰,盛立军,孙亚红,等.中药穴位贴敷联合耳穴按压治疗顺铂引起延迟性呕吐的临床观察[J].临床肿瘤学杂志,2010.3,15(3)：260-262.
[75]郁美娟,杨金洪,陈桂萍,等.针刺治疗放化疗所致造血功能损害的临床观察[J],中国针灸,1994,5：5-6.
[76]毕钰桢.电针防治恶性肿瘤化疗后骨髓抑制的临床研究[J],中国优秀硕士学位论文,2008.5.
[77]丁健萍.艾灸治疗化疗所致白细胞下降的疗效观察与护理[J],实用中西医结合临床,2010.5,10(3)：74-75.
[78]赵爱明,陆锦云,李拥军.艾灸治疗化疗所致白细胞减少症45例[J].长春中医学院学报,1999.3,15(77)：22.
[79]张开芳.穴位注射治疗化疗所致白细胞减少疗效观察[J],中国误诊学杂志,2004.3,4(3)：388-389.
[80]于成山,陶鸿飞.穴位注射治疗化疗后白细胞减少的临床观察[J].上海针灸杂志,2007.10,26(10)：11-12.
[81]陆凤枝,陈平.穴位注射治疗放化疗后血液白细胞计数减低200例[J].中医外治法杂志,2009,18(6)： 26.
[82]程俊.参附注射液穴位注射防治化疗骨’髓抑制临床观察[J].中国中医急症,2009.11,18(11)：1812-1813.
[83]杨燕艳,郑红薇,孙大志.重组人粒细胞集落刺激因子联合温针灸治疗消化道肿瘤化疗后骨髓 抑制的疗效[J].世界华人消化杂志,2006,14(36)：3525—3528.
[84]周峰,黄君英,薛俐.针药合用对化疗后白细胞减少症疗效观察[J],实用预防医学,2010.6,17(6)：1168-1170.
[85]李晓军,李秀华,刘亚书.灸法配合耳穴贴压治疗化疗所致不良反应32例[J].中国针灸,2001.9,21(9)：523-524.
[86]刘萍,刘艳,唐强,等.穴位注射配合艾灸治疗化疗后白细胞减少症的临床研究[J].辽宁中医杂志,2003,3：213.
[87]窭健卿,张辉,高文斌,等.针刺加穴位注射治疗化疗药物致骨髓抑制的临床观察与研究[J].中国针灸,2002,(5)：301-303.
[88]徐琳.针灸配合中药治疗白细胞减少症46例[J].针灸临床杂志,2003,(6)：17.
[89]张肖晗.针药并用治疗肿瘤化疗后骨髓抑制临床观察[J].中华实用中西医杂志,2007,20(6)：502-503.
[90]范钰,杨兆民,万铭,等.针灸防治恶性肿瘤化疗毒副反应的临床研究[J].上海针灸杂志,2001,20(1)：12.
[91]陈少宗,叶芳.电针疗法对肿瘤患者化疗过程中T细胞及NK细胞活性的影响[J].针灸上海针灸杂志,1999.10,18(5)：17-18.
[92]叶芳,刘德山,王淑丽,等.电针疗法对化疗患者T细胞亚群／NK细胞活性／体液免疫及白细胞计数的影响[J].南京中医药大学学报,2004.7,20(4)：212-213.
[93]叶芳,杨林,陈少宗.电针疗法对化疗患者免疫系统影响的观察[J],山东医药,2001,41(9)：33-34.
[94]张去飞,林国华.直接灸四花穴对肺癌化疗患者CSF、TNF、IL-2的影响[J],中国优秀硕士学位论文,2010.4.
[95]姜桂美.艾灸对肿瘤化疗后外周血淋巴细胞凋亡影响的研究[J],中国优秀硕士学位论文,2002.4.
[96]林滨,谢召平,廖小七,等.参麦注射液穴位注射对20例食管癌化疗患者免疫功能的疗效观察[J].福建中医药,2002.4,33(2)：12-13.
[97]李敏,陈小耐,樊青霞.按时取穴法穴位注射黄芪液对癌症化疗病人免疫功能的影响[J].针灸临床杂志,1996,12(11)：22-24.
[98]黄喜梅.电针足三里对癌症化疗中胃肠功能影响的临床及实验研究[J].上海针灸杂志,1996,15(3)： 11-13.
[99]杨丹红,江庆淇,许文波.“神阙”穴隔药灸对荷瘤化疗大鼠胃黏膜保护作用的研究[J].中国针灸,1999,19(8)：483.
[100]廖威,裴景春.针刺不同穴位防治顺铂致家兔消化道反应的实验研究[J].上海针灸杂志,2000.12,10(6)：35-36.
[101]赵喜新,王和平,田开宇,等.针灸对化疗小鼠骨髓粒系细胞动态变化的影响[J].中国针灸, 2000,3：172-174.
[102]闫杜海.针灸对荷瘤小鼠环磷酰胺化疗后白细胞及骨髓有核细胞总数的影响[J].河南中医,1997,17(3)：154-155.
[103]路枚,曹大明,李建伟.针灸对CTX化疗小鼠骨髓凋亡相关基因P53/bc]-2/bax蛋白表达的影响[J].世界针灸学会联合会成立20周年暨世界针灸学术大会论文摘要汇编：114-115.
[104]路枚,赵喜新,曹大明,等.针灸对CTX小鼠骨髓细胞周期调节的研究[J],中华中医药杂志,2008：169-171
[105]杨志新,乔跃兵,赵粹英.艾灸对荷瘤小鼠巨噬细胞免疫功能的增强作用[J],承德医学院学报,2002,11.2(97-99)
[106]施茵,指导：张安莉.针灸调节U14荷瘤小鼠红细胞免疫功能的实验研究[J].江西中医学院学报,2000,12(3)：111-113.
[107]裴建,于颖梅,魏海,等.艾灸调节肿瘤免疫抑制效应的实验研究[J].上海中医药杂志,2007,41(8)：1-4.
[108]苗利君,李敏,韩慧,等.子午流注取穴法穴位注射黄芪液对荷瘤小鼠免疫功能的影响[J].中医研究,1996,2.9(1)：19-22.
[109]尚明华,孙亦农.针灸对CTX化疗小鼠NK细胞活力的影响[J],江苏中医,1998,19(4)：45-46.
[110]孙亦农,查炜,尚明华.针灸足三里穴对化疗大鼠T-AOC的影响[J],南京中医药大学学报,2003,11.19(6)：360-361.
[111]查炜,孙亦农,尚明华.不同针灸刺激方法对荷瘤CTX化疗小鼠抗氧化系统的影响[J].针灸临床杂志,2000,16(3)：58-60.
[112]尚明华,孙亦农.针灸对环磷酰胺化疗小鼠脂质过氧化损伤的影响[J].上海针灸杂志,1998,17(1)：40-41.
[113]中华人民共和国医政司.《中国常见恶性肿瘤诊治规范》[M].北京：北京医科大学,中国协和医科大学联合出版社,1991：432-433.
[114]Sobin LH, Wittekind CH. TNM classification of malignant tumors.5thed. New York: Wiley-Liss,1997:93-100.
[115]Kondra S, Laishaam J, Ban J,et al. Integration of repair as a predictive marker fo r lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J].J Cliu Oncol,2010,28(20):3219-3226.
[116]黄友明,张金花.吉西他滨单药治疗老年晚期非小细胞肺癌的疗效分析[J].皖南医学院学报,2008,27(6)：425-426.
[117]Joan H, David H, Chundra P,et al. Comparison of four chemotherapy-reginens for adv anced non-small-cell lung cancer[J].N Engl JMed,2002,346(2):92-98.
[118]Hidetaka U, Ryoichi N, Akitan N, et al. A randomized phase Ⅱ trial of adjuvant chemo therapy with bi-weekly carboplitin plus paclitaxel versus carboplatin plus gemcitabi ne in patients with completely resected non-small-cell lung cancer[J]. Anticancer Res, 2010,30(11):4695-4699.
[119]孙燕,石远凯,王燕,等.临床肿瘤内科学[M]5版.北京：人民卫生出版社,2005：388-389.
[120]Monnet I, Brienza S, Hugret F, et al. PhaseⅡStudy of oxaliplatin in poor-progr ess non-small cell lung cancer(NSCLC) [J]. Eur J Cancer,1998,34(7):1124-1127.
[121]吴海鹰,管忠震,何友.国产紫杉醇治疗恶性肿瘤的III期临床研究报道[J].肿瘤,1998,18(6)：394.
[122]汤钊猷.现代肿瘤学[M].2版.上海：上海医科大学出版社,2000：807.
[123]刘显红,张彩,鲍慧铮,等.紫杉醇治疗晚期非小细胞肺癌48例疗效分析[J].实用肿瘤学杂志,1998,12(1)：56.
[124]罗海鸥,唐勇,蒲艺,等.火针对类风湿关节炎大鼠TNF-a的影响[J].辽宁中医学院学报,2003,5,5(2)：167.
[125]张晓霞,董明霞,陶云.火针疗法对外周血象影响的临床观察[J].北京中医,2003,8,22(4)： 47-48.
[2]游伟程.常见恶性肿瘤的流行情况[J].中华医学信息导报,2005,20(22)：22.
[3]PirozynskiM.100 years of lung cancer[J]. Respir M ed,2006,100(12):2073-2084.
[4]KenjiW, Manami I, Tetsuya M, et al. Tobacco Smoking and Lung Cancer Risk:An Evalu ation Based on a Systematic Review of Epidemio-logical Evidence Among the Japanese P opulation[J]. Japanese Journal of Clinical Oncology,2006,36(5):309-324.
[5]Edwards R, PlessMT, HowelD, et al.Does living near heavy industry cause lung cane er in women? A case-control study using life grid inter-views[J]. Thorax,2006,61(1 2):1076-1082.
[6]Ignatius TS, Yuk LC, Joseph SK, et al.Dose-Response Relationship between Cooking Fumes Exposures and Lung Cancer among Chinese Non-smoking Women [J].Cancer Research, 2006,66(8):4961-4967.
[7]Darby S, HillD, DeoH, et al,Residential radon and lung cancer detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14 208 persons without lung cancer from 13 epidemiologic studies in Europe[J]. Scand J W ork Environ Health,2006,32(Suppll):1-83.
[8]Bellil Y, Edelman M J. Bronchogenic carcinoma in solid organ transplant recipients [J].Curr Treat Options Oncol,2006,7(1):77-81.
[9]Jun-ichiN, Manami I, Motoki I, et al. Association Between Lung Cancer Incidence and Family History of Lung Cancer [J]. Chest,2006,130:968-975.
[10]战忠利,孙雷娜.WHO 2004年版肺癌组织学分类与临床意义[J].中国肿瘤影像学,2009,2(2)：145-147.
[11]Pignon JP, Tribodet H, Scrag liotti G,et al.Lung Adjuvant Cisplstin Evaluation(LAC E):A pooled analysis of five randomized clinical trials including 4,584patients [J]. J C lin Oncol,2006,24:366.
[12]Stewart LA, Burdett S, Tiemey JF, et al. Surgery and adjuvant chemo-therapy(CT)compa red to surgery alone in nonsmall cell lung cancer(NSCLS):A meta-analysis using indiv idual patient data(IPD)from random ized clinical trials (RCT)[J]. JC lin Oncol,2007,25: 397.
[13]Scag liottiG, FossatiR, TorriV, et al. Randomized study of adjuvant chemotherapy for completely resected stage Ⅰ, Ⅱ, orⅢ Anon-small-cell lung cancer[J].JN atlCancer In st,2003,95:1453-1461.
[14]Arriagada R,Bergm an B,DunantA, et al. Cisplatin-based adjuvant chemotherapy in pa tients with completely resected non-small-cell lung cancers[J].N EnglJMed,2004,350:3 51-360.
[15]Winton T, Livingston R,Johnson D, et al. Vinorelbine plus cisplatin observation in reseceted non-small-cell lung cancers[J].N Engl JMed,2005,352:2589-2597.
[16]Strauss G,Hemdon J,Maddaus M, et al. Adjuvant chemotherapy in stage IB non-small-c ell lung cancers(NSCLC):Update of Cancer and Leukemia GroupB(CALGB)protoco19633[J].J Clin Oncol,2006,24:365.
[17]Douillard JY,Rosell R, DeLena M, et al. Adjuvant vinorelbine plus cisplatin versus observationg in patients with completely resected stage ⅠB—ⅢA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association ANIIA):A randomized con trolled trial [J]. Lancet Oncol,2006,7:719-727.
[18]孙威.非小细胞肺癌治疗进展[J].中华现代外科学杂志,2005,2(1)：60-62.
[19]PORT Meta-analysis Trialists Group, Postperative radiotherapy for non-small-cell lung Cancer[J]. G. The Cochrane Database of System Reviews,2005, Issue 2.
[20]Okawara G,Postoperative radiotherapy in stage Ⅱ or ⅢA completely resected non-small cell lung cancer a systematic review and practice guideline[J]. Lung Cancer,20 04,44:1-11.
[21]Choy H,Akerley Wsfran H. Multi institutional phase Ⅱ traill of paclitaxel, carbop latin and concurrent radiation therapy for locally advancednon-small-celllungcancer [J].JClinOncol,1998,16(10):3316-3322.
[22]Sandler AB, GrayR, Brahmer J, et al Paclitaxel-caboplatin alone or with bevacizumab for non-small cell lungcancer[J]. NEnglJMed,2006,355:2542-2550.
[23]夏述燕,赵体玉.术中125I放射性粒子种植治疗局部晚期非小细胞肺癌的手术配合[J].现代护理,2008,14(4)：524-525.
[24]艾星浩,陆舜,廖美琳.肺癌以手术为主的多学科综合治疗进展[J].中国肺癌杂志,2003,6(6)：441-443.
[25]孙燕.常见肿瘤综合治疗的进展.第八届全国临床肿瘤大会
[26]Dan L, Zhu B, Chen Z. Meta—analysis of the literature:Neoadjuvant chemotherapy versus surgery alone in non-small cell lung cancer[J]. J Clin Oncol,2008,26:a7580.
[27]Ciuleanu TE, Brodow icz T, Belani CP, et al. Maintenance pemetrexed plus best suppor tive care (BSC)versus placebo plus BSC;A phase Ⅲstudy [J].JClin Oncol,2008,26(Supp 1):8001.
[28]E1-Shenshawy HM. FathyA, Eteba S, et al. Sequential chemora-diotherapy versus concur rent chemoradio therapy plus consolilation chemotherapy in unresecetable stage III n on-small cell lung cancer [J].JClin Oncol,2008,26:18509.
[29]马玉英.肺癌的生物治疗研究与进展[J].中国医学研究与临床,2008,6(6)：35-41.
[30]Krause I,Valesini G, Scrivo R, Sheonfeld Y. Autoimmune aspects of cytokine and anti cytokine therapies[J]. Am Med,2003,115(5):390-7.
[31]朱小花,田应选.肺癌生物分子靶向治疗研究进展[J].实用医技杂志,2006,13(16)：492.
[32]Sandler AB,Gray R, Brahmer J, et al Paclitaxel-carboplatin alone or with bevacizum ab for non-small cell lungcaner[J]. N Engl JMed,2006,355:2542-2550.
[33]Ono M, Kuwano, LMolecular mechanisms of epidermal growth factor eceptor activatio n and response to gefitinib and other EGFR-targeting drugs [J].Clin Cancer Ras,2006, 12(24):7242.
[34]彭勇,张靓.非小细胞肺癌治疗进展研究[J].中国现代药物应用,2008,2(2)：95.
[35]任淑华,王井伟,刘长宏,等.肺癌患者血清中IL-2和TNF水平变化的临床意义[J].中国煤炭工业医学杂志,2002,15(5)：315.
[36]邹建文,程征,王大华.肺癌患者血清中IL-2,TNF-a测定的临床意义[J].放射免疫学杂志,2002,15(5)：315.
[37]孙昕.肺癌患者血清TNF-a和IL-6水平观察及临床意义[J].安徽医科大学学报,2001,36(1)：45-46.
[38]叶建增,申维玺,马慧利,等.TGF-β 1、TNF-α与癌症相关性乏力关系的免疫组化研究[J].医学研究杂志,2008,5(37)：38-40.
[39]XU, FU XY. Plate IFN-gammia induces cell growth inhibition by Fas-mediated apoptos is:uequirement of STATL. protein for up regulation of Fasand Faslexpression[J]. Cancer Res,1998,58(2):2832-2833.
[40]Ordirura M, Romano C, De Vita F, et al, Behaviour of interleukin-2 serum levels in a dvanced non-small cell lung cancer patients:relationship with responset otherapy and survival[J]. CancerImmunolImmunother,2009,49(10):530-536.
[41]Fischer JR,Schindel M, Bulzebruck H, et al. Long-term survival in small cell lung c ancer patients is correlated with high inteleukin-2 secretion at diagnosis[J]. JCance rResClinOncol,2000,126(12):730-73.
[42]张晓菊,张劲农,张建初.检测肺癌所致胸腔积液中Sil-2R的临床应用价值研究[J].新医学,2007,38(4)：232-233.
[43]陈晓琳,戴勇,李富荣,等.恶性肿瘤患者T细胞及NK细胞功能研究及临床意义[.T].中国现代医学杂志,2002,12(2)：41-43.
[44]李进东,许金良,王文光,等.肺癌患者外周血T细胞亚群的变化[J],中国医师进修杂志,2006,29(11)：25-27.
[45]姜维洁,董静懿.肺癌患者血管内皮生长因子和T细胞亚群表达的变化[J].标记免疫分析与临床,2006,13(4)：201-202.
[46]Nishikawa H. Kato T, Tawara Isao, et al, IFN-r controls the generation/activation of CD4+ CD25+ regulatory Tcells in antitum or immune response[J]. J Immunol,2005,175(7):44 33-4440.
[47]张敬川,王红兵,高超,等.非小细胞肺癌患者T细胞亚群变化的临床意义[J].徐州医学院学报,2002,22(6)：537-538.
[48]狄松波,陈清勇.非小细胞肺癌患者化疗前后细胞免疫功能的变化[J].实用医学杂志,2009,25(14)：2341-2342.
[49]黄谦,朱慕云,卞京文.肺癌患者IL-6及T淋巴细胞亚群检测的实验研究[J].江苏临床医学杂志,2001,5(6)：498-500.
[50]李和根.刘嘉湘教授以扶正法为主治疗肺癌经验[J].四川中医,2005,23(7)：5-6.
[51]刘嘉湘,施志明,徐振华,等.滋阴生津益气温阳法治疗晚期原发性肺癌的临床研究[J].中医杂志,1995,36(3)：155-158.
[52]吴玉生.肺癌病因病机与临床治疗[J].新中医,2005,37(8)：3-4.
[53]李际强,罗翌,徐凯.刘伟胜教授治疗肺癌经验介绍[J].新中医,2007,39(3)：99-100.
[54]张霆.从伏气学说探讨肺癌之病因病机[J].中医研究,2007,20(3)：5-7.
[55]郑红刚,花宝金.朴炳奎辨证治疗肺癌的学术思想[J].北京中医,2007,26(5)：273-275.
[56]高雪艳,林动,陈家俊.四君子汤为主在肺癌化疗过程中减轻胃肠道反应的观察[J].海峡药学,2009,21(12)：182-183.
[57]张东焱,郑燕飚,汪力慧,等.半苏散敷脐治疗肺癌化疗呕吐反应临床观察[J].中国误诊学杂志,2009.6,9(16)：3819-3820.
[58]杨祖贻,罗洁.中药对Ⅲ-Ⅳ期肺癌患者化疗骨髓抑制及生活质量的影响[J].四川中医,2003,23(2)：10-12.
[59]刘展华,史建文.复方阿胶浆对肺癌化疗增效减毒作用的临床观察[J].中华中医药学刊,2007,11.15(11)：2427-2428.
[60]吴小明.补肾健脾中药降低中晚期肺癌化疗毒副反应效果观察[J].中医药临床杂志,2010,10.22(5)：394-395.
[61]张印,郭建刚.复方阿胶浆对肺癌化疗增效减毒作用的临床观察[J].第四军医大学报,2005,26(13)：1219-1220.
[62]李兴琴,徐增年,周俊琴.“保肺泰”对C57BL/6J荷瘤小鼠及化疗荷瘤小鼠NK细胞活性的影响[J].实验动物科学与管理,2000,3.17(1)：27-29.
[63]杨焱,张越,景年才,等.电针足三里穴治疗恶性肿瘤化疗所致恶心呕吐：多中心随机对照研究[J].中国针灸,2009,12.29(12)：955-978.
[64]陈闯,张作军,黎汉忠,等.电针足三里穴对化疗减毒作用的临床观察[J].新中医,2004,3(3 6)： 46-47.
[65]李爱华.针刺治疗肝癌介入化疗栓塞术后顽固性呃逆疗效观察[J],湖北中医杂志,2005,27(7)： 38.
[66]唐玲.艾灸治疗化疗后胃肠道反应[J],中医外治杂志,2001,10(5)：48.
[67]李柳宁,孔怡琳,刘丽荣,等.雷火灸对含铂类药物化疗所致消化道反应25例[J].陕西中医,2009,30(7)：886-887.
[68]沈国伟,肖扬.针灸足三里对抗化疗呕吐反应临床研究[J].中国针灸,2001,21(3)：158-160.
[69]沈国伟.针灸对化疗呕吐患者胃电频谱分布和波形的影响[J].中国针灸,2001,(9)：7-8.
[70]沈国伟,赵京生.针灸对化疗呕吐患者的胃动力学影响[J].上海针灸杂志,2003,22(3)：18-21.
[71]彭秩霞,张亚密,潘改燕.足三里穴位注射防治化疗后消化道反应30例[J].陕西中医学院学报,2009.05,32(3)：33.
[72]闫文针.胃复安维生素B6针穴位注射治疗化疗后胃肠道反应疗效观察[J],中国误诊学杂志,2010.7,10(20)：4836.
[73]刑晓娟.电针加耳穴贴压治疗化疗引起的呕吐54例疗效比较[J],第四军医大学学报,2009,30(3)：354.
[74]王淑兰,盛立军,孙亚红,等.中药穴位贴敷联合耳穴按压治疗顺铂引起延迟性呕吐的临床观察[J].临床肿瘤学杂志,2010.3,15(3)：260-262.
[75]郁美娟,杨金洪,陈桂萍,等.针刺治疗放化疗所致造血功能损害的临床观察[J],中国针灸,1994,5：5-6.
[76]毕钰桢.电针防治恶性肿瘤化疗后骨髓抑制的临床研究[J],中国优秀硕士学位论文,2008.5.
[77]丁健萍.艾灸治疗化疗所致白细胞下降的疗效观察与护理[J],实用中西医结合临床,2010.5,10(3)：74-75.
[78]赵爱明,陆锦云,李拥军.艾灸治疗化疗所致白细胞减少症45例[J].长春中医学院学报,1999.3,15(77)：22.
[79]张开芳.穴位注射治疗化疗所致白细胞减少疗效观察[J],中国误诊学杂志,2004.3,4(3)：388-389.
[80]于成山,陶鸿飞.穴位注射治疗化疗后白细胞减少的临床观察[J].上海针灸杂志,2007.10,26(10)：11-12.
[81]陆凤枝,陈平.穴位注射治疗放化疗后血液白细胞计数减低200例[J].中医外治法杂志,2009,18(6)： 26.
[82]程俊.参附注射液穴位注射防治化疗骨’髓抑制临床观察[J].中国中医急症,2009.11,18(11)：1812-1813.
[83]杨燕艳,郑红薇,孙大志.重组人粒细胞集落刺激因子联合温针灸治疗消化道肿瘤化疗后骨髓 抑制的疗效[J].世界华人消化杂志,2006,14(36)：3525—3528.
[84]周峰,黄君英,薛俐.针药合用对化疗后白细胞减少症疗效观察[J],实用预防医学,2010.6,17(6)：1168-1170.
[85]李晓军,李秀华,刘亚书.灸法配合耳穴贴压治疗化疗所致不良反应32例[J].中国针灸,2001.9,21(9)：523-524.
[86]刘萍,刘艳,唐强,等.穴位注射配合艾灸治疗化疗后白细胞减少症的临床研究[J].辽宁中医杂志,2003,3：213.
[87]窭健卿,张辉,高文斌,等.针刺加穴位注射治疗化疗药物致骨髓抑制的临床观察与研究[J].中国针灸,2002,(5)：301-303.
[88]徐琳.针灸配合中药治疗白细胞减少症46例[J].针灸临床杂志,2003,(6)：17.
[89]张肖晗.针药并用治疗肿瘤化疗后骨髓抑制临床观察[J].中华实用中西医杂志,2007,20(6)：502-503.
[90]范钰,杨兆民,万铭,等.针灸防治恶性肿瘤化疗毒副反应的临床研究[J].上海针灸杂志,2001,20(1)：12.
[91]陈少宗,叶芳.电针疗法对肿瘤患者化疗过程中T细胞及NK细胞活性的影响[J].针灸上海针灸杂志,1999.10,18(5)：17-18.
[92]叶芳,刘德山,王淑丽,等.电针疗法对化疗患者T细胞亚群／NK细胞活性／体液免疫及白细胞计数的影响[J].南京中医药大学学报,2004.7,20(4)：212-213.
[93]叶芳,杨林,陈少宗.电针疗法对化疗患者免疫系统影响的观察[J],山东医药,2001,41(9)：33-34.
[94]张去飞,林国华.直接灸四花穴对肺癌化疗患者CSF、TNF、IL-2的影响[J],中国优秀硕士学位论文,2010.4.
[95]姜桂美.艾灸对肿瘤化疗后外周血淋巴细胞凋亡影响的研究[J],中国优秀硕士学位论文,2002.4.
[96]林滨,谢召平,廖小七,等.参麦注射液穴位注射对20例食管癌化疗患者免疫功能的疗效观察[J].福建中医药,2002.4,33(2)：12-13.
[97]李敏,陈小耐,樊青霞.按时取穴法穴位注射黄芪液对癌症化疗病人免疫功能的影响[J].针灸临床杂志,1996,12(11)：22-24.
[98]黄喜梅.电针足三里对癌症化疗中胃肠功能影响的临床及实验研究[J].上海针灸杂志,1996,15(3)： 11-13.
[99]杨丹红,江庆淇,许文波.“神阙”穴隔药灸对荷瘤化疗大鼠胃黏膜保护作用的研究[J].中国针灸,1999,19(8)：483.
[100]廖威,裴景春.针刺不同穴位防治顺铂致家兔消化道反应的实验研究[J].上海针灸杂志,2000.12,10(6)：35-36.
[101]赵喜新,王和平,田开宇,等.针灸对化疗小鼠骨髓粒系细胞动态变化的影响[J].中国针灸, 2000,3：172-174.
[102]闫杜海.针灸对荷瘤小鼠环磷酰胺化疗后白细胞及骨髓有核细胞总数的影响[J].河南中医,1997,17(3)：154-155.
[103]路枚,曹大明,李建伟.针灸对CTX化疗小鼠骨髓凋亡相关基因P53/bc]-2/bax蛋白表达的影响[J].世界针灸学会联合会成立20周年暨世界针灸学术大会论文摘要汇编：114-115.
[104]路枚,赵喜新,曹大明,等.针灸对CTX小鼠骨髓细胞周期调节的研究[J],中华中医药杂志,2008：169-171
[105]杨志新,乔跃兵,赵粹英.艾灸对荷瘤小鼠巨噬细胞免疫功能的增强作用[J],承德医学院学报,2002,11.2(97-99)
[106]施茵,指导：张安莉.针灸调节U14荷瘤小鼠红细胞免疫功能的实验研究[J].江西中医学院学报,2000,12(3)：111-113.
[107]裴建,于颖梅,魏海,等.艾灸调节肿瘤免疫抑制效应的实验研究[J].上海中医药杂志,2007,41(8)：1-4.
[108]苗利君,李敏,韩慧,等.子午流注取穴法穴位注射黄芪液对荷瘤小鼠免疫功能的影响[J].中医研究,1996,2.9(1)：19-22.
[109]尚明华,孙亦农.针灸对CTX化疗小鼠NK细胞活力的影响[J],江苏中医,1998,19(4)：45-46.
[110]孙亦农,查炜,尚明华.针灸足三里穴对化疗大鼠T-AOC的影响[J],南京中医药大学学报,2003,11.19(6)：360-361.
[111]查炜,孙亦农,尚明华.不同针灸刺激方法对荷瘤CTX化疗小鼠抗氧化系统的影响[J].针灸临床杂志,2000,16(3)：58-60.
[112]尚明华,孙亦农.针灸对环磷酰胺化疗小鼠脂质过氧化损伤的影响[J].上海针灸杂志,1998,17(1)：40-41.
[113]中华人民共和国医政司.《中国常见恶性肿瘤诊治规范》[M].北京：北京医科大学,中国协和医科大学联合出版社,1991：432-433.
[114]Sobin LH, Wittekind CH. TNM classification of malignant tumors.5thed. New York: Wiley-Liss,1997:93-100.
[115]Kondra S, Laishaam J, Ban J,et al. Integration of repair as a predictive marker fo r lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J].J Cliu Oncol,2010,28(20):3219-3226.
[116]黄友明,张金花.吉西他滨单药治疗老年晚期非小细胞肺癌的疗效分析[J].皖南医学院学报,2008,27(6)：425-426.
[117]Joan H, David H, Chundra P,et al. Comparison of four chemotherapy-reginens for adv anced non-small-cell lung cancer[J].N Engl JMed,2002,346(2):92-98.
[118]Hidetaka U, Ryoichi N, Akitan N, et al. A randomized phase Ⅱ trial of adjuvant chemo therapy with bi-weekly carboplitin plus paclitaxel versus carboplatin plus gemcitabi ne in patients with completely resected non-small-cell lung cancer[J]. Anticancer Res, 2010,30(11):4695-4699.
[119]孙燕,石远凯,王燕,等.临床肿瘤内科学[M]5版.北京：人民卫生出版社,2005：388-389.
[120]Monnet I, Brienza S, Hugret F, et al. PhaseⅡStudy of oxaliplatin in poor-progr ess non-small cell lung cancer(NSCLC) [J]. Eur J Cancer,1998,34(7):1124-1127.
[121]吴海鹰,管忠震,何友.国产紫杉醇治疗恶性肿瘤的III期临床研究报道[J].肿瘤,1998,18(6)：394.
[122]汤钊猷.现代肿瘤学[M].2版.上海：上海医科大学出版社,2000：807.
[123]刘显红,张彩,鲍慧铮,等.紫杉醇治疗晚期非小细胞肺癌48例疗效分析[J].实用肿瘤学杂志,1998,12(1)：56.
[124]罗海鸥,唐勇,蒲艺,等.火针对类风湿关节炎大鼠TNF-a的影响[J].辽宁中医学院学报,2003,5,5(2)：167.
[125]张晓霞,董明霞,陶云.火针疗法对外周血象影响的临床观察[J].北京中医,2003,8,22(4)： 47-48.